# To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT01256736** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 89 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** DMARDs

## Key facts

- **NCT ID:** NCT01256736
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-12
- **Final completion:** 2013-11
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2013-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256736, "To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01256736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*